Abstract: Objective To establish a detection process for drug-induced immune thrombocytopenia (DITP) caused by piperacillin-tazobactam sodium, and to provide timely diagnostic criteria for clinical diagnosis of DITP. Methods Platelet antibody screening was conducted using the solid-phase agglutination method. The solid-phase agglutination method was employed in the detection system to test for piperacillin-tazobactam sodium and omeprazole dependent platelet antibodies. In vitro red blood cell sensitization was performed using the anti-human globulin method to detect drug antibodies against piperacillin-tazobactam sodium on red blood cells. The patients were followed up at 1, 2, 5, and 8 days post drug withdrawal to investigate the potency of piperacillin-tazobactam sodium-dependent platelet drug antibodies and observe trends in platelet counts. Results A patient who received piperacillin-tazobactam sodium for 13 days experienced a significant decrease in platelet count and developed bleeding symptoms, which were attributed to the presence of piperacillin-tazobactam sodium-dependent platelet drug antibodies. Conclusion The solid-phase agglutination method incorporating piperacillin-tazobactam sodium can be utilized as a rapid diagnostic tool for detecting drug-dependent platelet antibodies.

Key words: Drug-induced immune thrombocytopenia, Piperacillin-tazobactam sodium, Platelet antibody screening, Drug-dependent platelet antibodies